Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 19;10(4):373-380.
doi: 10.1097/APO.0000000000000360.

Outcomes of Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma Based on Patient Age in 964 Eyes of 554 Patients

Zeynep Bas  1 , Lauren A Dalvin  1   2 , Sameeksha Tadepalli  1 , Raksha Rao  1 , Amish Shah  3 , Ann M Leahey  3 , Carol L Shields  1
Affiliations
Free article

Outcomes of Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma Based on Patient Age in 964 Eyes of 554 Patients

Zeynep Bas et al. Asia Pac J Ophthalmol (Phila). .
Free article

Abstract

Purpose: To evaluate retinoblastoma control after intravenous chemotherapy (chemoreduction) by patient age at presentation.

Design: Retrospective case series.

Methods: This study included 964 eyes of 554 patients treated with chemoreduction at Ocular Oncology Service at Wills Eye Hospital. Patients received 6 monthly cycles of standard chemoreduction. Additional therapies for tumor control were performed as needed.

Results: Of 964 eyes, a comparison by age group (<6 months vs. 6-12 months vs. 13-24 months vs. >24 months) revealed more advanced age group with higher frequency of group E tumor (15% vs. 25% vs. 32% vs. 39%, P < 0.001). By treatment outcomes, complete tumor control was achieved with chemoreduction alone more often in less advanced age group (46% vs. 30% vs. 17% vs. 8%, P < 0.001). Additional treatment after chemoreduction was needed more often in more advanced age group with external beam radiotherapy (EBRT; 9% vs. 16% vs. 20% vs. 15%, P = 0.006) or enucleation (12% vs. 18% vs. 26% vs. 37%, P < 0.001). Over time (1994-1998 vs. 1999-2003 vs. 2004-2008 vs. 2009-2013 vs. 2014-2019), the paradigm for additional required treatment after chemoreduction shifted toward less EBRT (27% vs. 24% vs. 14% vs. 7% vs. 2%, P < 0.001) and more intra-arterial (0% vs. 0% vs. 1% vs. 25% vs. 48%, P < 0.001) and intravitreal (0% vs. 0% vs. 3% vs. 10% vs. 20%, P < 0.001) chemotherapy.

Conclusions: Chemoreduction is a safe and effective treatment method for patients with retinoblastoma, demonstrating the best tumor control in the younger age groups.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Shields JA, Shields CL. Management and prognosis of retinoblastoma. In: Shields JA, ed. Intraocular Tumors: A Text and Atlas. Philadelphia, PA: WB Saunders; 1992:377–392.
    1. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control 2004; 11:317–327.
    1. Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of retinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmol 2015; 133:1341–1347.
    1. Shields CL, Meadows AT, Leahey AM, Shields JA. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina 2004; 24:849–862.
    1. Shields CL, Shields JA. Editorial: chemotherapy for retinoblastoma. Med Pediatr Oncol 2002; 38:377–378.

LinkOut - more resources